Stay updated on Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page.

Latest updates to the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page footer now displays revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe ClinicalTrials.gov record for a phase II study of nivolumab and ipilimumab in mucinous colorectal and appendiceal tumors is displayed, with study details, eligibility criteria, locations, and outcome measures. The study is marked terminated due to slow enrollment and lack of efficacy.SummaryDifference49%

- Check22 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 error.SummaryDifference0.2%

- Check29 days agoChange DetectedA banner announces NIH website transition updates and notes that NIH content may use “Super Intelligence” instead of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check43 days agoChange DetectedThe site revision shown in the footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page.